|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women.
|
30898391 |
2019 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Identification of nine new susceptibility loci for endometrial cancer.
|
30093612 |
2018 |
|
mathematical ability
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.
|
30038396 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
|
Obesity
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association study on obesity and obesity-related traits.
|
21552555 |
2011 |
|
Obesity
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
A genome-wide association study on obesity and obesity-related traits.
|
21552555 |
2011 |
|
Longevity
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Joint influence of small-effect genetic variants on human longevity.
|
20834067 |
2010 |
|
Longevity
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Joint influence of small-effect genetic variants on human longevity.
|
20834067 |
2010 |
|
Down Syndrome
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that synapse maturation is inhibited in NCAM2-overexpressing neurons and suggest that changes in NCAM2 levels and altered submembrane Ca2+ dynamics can cause defects in synapse maturation in Down syndrome and other brain disorders associated with abnormal NCAM2 expression.
|
29522129 |
2019 |
|
Complete Trisomy 21 Syndrome
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that synapse maturation is inhibited in NCAM2-overexpressing neurons and suggest that changes in NCAM2 levels and altered submembrane Ca2+ dynamics can cause defects in synapse maturation in Down syndrome and other brain disorders associated with abnormal NCAM2 expression.
|
29522129 |
2019 |
|
Autistic Disorder
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
NCAM2 deletion in a boy with macrocephaly and autism: Cause, association or predisposition?
|
27596683 |
2016 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our data indicate that Aβ-dependent disruption of NCAM2 functions in AD hippocampus contributes to synapse loss.
|
26611261 |
2015 |
|
Alzheimer's Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Two genes found to be near the top SNPs, CYP19A1 (rs2899472, p = 1.90 × 10(-7)) and NCAM2 (rs1022442, p = 2.75 × 10(-7)) have been reported as genetic factors related to the progression of AD from previous studies.
|
20932310 |
2010 |
|
Autistic Disorder
|
0.020 |
Biomarker
|
disease |
BEFREE |
The deletion involves 19 genes, including NCAM2 and GRIK1, both of which are associated with normal brain development and function, and have been considered as possible candidate genes in autism and other neurobehavioral disorders.
|
20034085 |
2010 |
|
Down Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
In addition, the role of NCAM2 in the pathophysiology of Down syndrome is unknown.
|
9226371 |
1997 |
|
Complete Trisomy 21 Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
In addition, the role of NCAM2 in the pathophysiology of Down syndrome is unknown.
|
9226371 |
1997 |
|
Brain Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Our results indicate that synapse maturation is inhibited in NCAM2-overexpressing neurons and suggest that changes in NCAM2 levels and altered submembrane Ca2+ dynamics can cause defects in synapse maturation in Down syndrome and other brain disorders associated with abnormal NCAM2 expression.
|
29522129 |
2019 |
|
Macrocephaly
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
NCAM2 deletion in a boy with macrocephaly and autism: Cause, association or predisposition?
|
27596683 |
2016 |
|
Autism Spectrum Disorders
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our reported case raises the questions whether the NCAM2-deletion is the true cause of the ASD or only a risk factor and whether there might be any connection in NCAM2 with skull-size
|
27596683 |
2016 |
|
Intellectual Disability
|
0.010 |
GeneticVariation
|
group |
BEFREE |
SNP microarray and whole exome sequencing identified a homozygous frameshift mutation (p.L870V) in SCARF2 and predicted damaging mutations in several genes, most notably DGCR2 (p.P75L) and NCAM2 (p.S147G), both possible candidates for this child's intellectual disability.
|
27375131 |
2016 |
|
Muscular fasciculation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Poor axonal growth and fasciculation is observed in animal models deficient for NCAM2.
|
25464110 |
2015 |
|
Neurodevelopmental Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
21q21 deletion involving NCAM2: report of 3 cases with neurodevelopmental disorders.
|
25464110 |
2015 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, NCAM2 should be a novel gene therapy target for the treatment of prostate and breast cancer.
|
21214674 |
2011 |